Mozafancogene autotemcel

莫柯基奥干赛

Report date: 2024/09/06 14:07:46

Base Information

Drug NameMozafancogene autotemcel

Drug Alias NameRP-L02RP-L102LV-RP-L102RP L102

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionFANCA gene transference

TargetsFanconi anemia group A protein

Therapy Area/IndicationsFanconi Anemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited KingdomSpain +[4]

CombinationsNo

Global Highest StatusNDA/BLA

Highest Status in ChinaN/A

Originator CompaniesCentre For Research On Energy, Environment And Technology

China Registration ClassN/A

Develop Information

Active CompaniesRocket Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsFanconi Anemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A